Fundraising Fox

AnHeart Therapeutics

3 known investors

Biopharma, acquired by Nuvation Bio (葆元医药)

Investors · 3

Cenova CapitalShanghai
Decheng CapitalMenlo Park
Vertex Ventures ChinaSingapore · $2M – $85M

In the news

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer - BioSpacebiospace.com · Mar 2024AnHeart beats its way to $61m series B - Global Venturingglobalventuring.com · Dec 2021With First Patients Dosed, AnHeart Snags $61 Million for Lung Cancer Hopeful - BioSpacebiospace.com · Dec 2021AnHeart Therapeutics Raises $61M in Series B Financingfinsmes.com · Dec 2021AnHeart Announces Entry into Series A+ Equity Financing Agreementsglobenewswire.com · Aug 2020AnHeart Announces Entry into Series A+ Equity Financing AgreementsProceeds to be Used for Advancing Taletrectinib Phase 2 Trials and Expanding Oncology Portfolio - BioSpacebiospace.com · Aug 2020

Frequently asked questions

What does AnHeart Therapeutics do?
Biopharma, acquired by Nuvation Bio (葆元医药)
Who are AnHeart Therapeutics's investors?
AnHeart Therapeutics's investors include Cenova Capital, Decheng Capital, Vertex Ventures China.